๐Ÿ”ฌDeep Research

BCAX โ€” Bicara Therapeutics Inc ยท catalysts, narrative & risks

ยท16 sourcesBCAX forecast โ†’

Bicara Therapeutics Inc. (Nasdaq: BCAX) โ€” Point-in-Time Profile (as of 2026-10-11)

Company snapshot: Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa (BCA101), a first-in-class EGFR/TGF-ฮฒ bifunctional antibody designed to break barriers in the tumor microenvironment [1], [7], [9]. The company is based in Boston/Cambridge, Massachusetts [9], [16], [17]. Shares traded near $17.50 on October 9, 2026, with a market capitalization of approximately $1.16B, sitting in a 52-week range of $13.70โ€“$30.99 [9], [16], [17]. This is not investment advice.


Recent Catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’